|
2019 Conference Publication Design and clinical validation of surface enhanced Raman spectroscopy nanodiagnostic technology for urinary prostate cancer risk predictionGardiner, F., Koo, K., Wang, J., Richards, R., Farrell, A., Yaxley, J., Samaratunga, H., Teloken, P., Roberts, M., Coughlin, G., Lavin, M., Mainwaring, P., Wang, Y., Gardiner, R. and Trau, M. (2019). Design and clinical validation of surface enhanced Raman spectroscopy nanodiagnostic technology for urinary prostate cancer risk prediction. Annual Scientific Meeting of the Urological Society of Australia and New-Zealand, Brisbane, QLD Australia, 13-16 April 2019. Chichester, West Sussex United Kingdom: Wiley-Blackwell. |
|
2018 Journal Article Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarkerSina, Abu Ali Ibn, Carrascosa, Laura G., Liang, Ziyu, Grewal, Yadveer S., Wardiana, Andri, Shiddiky, Muhammad J. A., Gardiner, Robert A., Samaratunga, Hemamali, Gandhi, Maher K., Scott, Rodney J., Korbie, Darren and Trau, Matt (2018). Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nature Communications, 9 (1) 4915, 4915. doi: 10.1038/s41467-018-07214-w |
|
2018 Journal Article The current status of renal cell carcinoma and prostate carcinoma gradingDelahunt, Brett, Egevad, Lars, Yaxley, John and Samaratunga, Hemamali (2018). The current status of renal cell carcinoma and prostate carcinoma grading. International Braz J Urol, 44 (6), 1057-1062. doi: 10.1590/S1677-5538.IBJU.2018.06.01 |
|
2018 Journal Article MRI-guided in-bore biopsy for prostate cancer: what does the evidence say?: a case series of 554 patients and a review of the current literaturePokorny, Morgan, Kua, Boon, Esler, Rachel, Yaxley, John, Samaratunga, Hemamali, Dunglison, Nigel, Gianduzzo, Troy, Coughlin, Geoff, Holt, Ross, Laing, Barbara, Ault, Darren, Brown, Nicholas, Parkinson, Rob and Thompson, Les (2018). MRI-guided in-bore biopsy for prostate cancer: what does the evidence say?: a case series of 554 patients and a review of the current literature. World Journal of Urology, 37 (7), 1263-1279. doi: 10.1007/s00345-018-2497-y |
|
2018 Journal Article Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?Ng, K. L., Del Vecchio, S. J., Samaratunga, H., Morais, C., Rajandram, R., Vesey, D. A., Wood, S. T. and Gobe, G. C. (2018). Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?. Pathology, 50 (5), 504-510. doi: 10.1016/j.pathol.2018.01.007 |
|
2018 Journal Article Design and clinical verification of surface-enhanced Raman spectroscopy diagnostic technology for individual cancer risk predictionKoo, Kevin M., Wang, Jing, Richards, Renée S., Farrell, Aine, Yaxley, John W., Samaratunga, Hema, Teloken, Patrick E., Roberts, Matthew J., Coughlin, Geoffrey D., Lavin, Martin F., Mainwaring, Paul N., Wang, Yuling, Gardiner, Robert A. and Trau, Matt (2018). Design and clinical verification of surface-enhanced Raman spectroscopy diagnostic technology for individual cancer risk prediction. ACS Nano, 12 (8), 8362-8371. doi: 10.1021/acsnano.8b03698 |
|
2018 Journal Article Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled studyCoughlin, Geoffrey D., Yaxley, John W., Chambers, Suzanne K., Occhipinti, Stefano, Samaratunga, Hema, Zajdlewicz, Leah, Teloken, Patrick, Dunglison, Nigel, Williams, Scott, Lavin, Martin F. and Gardiner, Robert A. (2018). Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. The Lancet Oncology, 19 (8), 1051-1060. doi: 10.1016/S1470-2045(18)30357-7 |
|
2018 Journal Article Utility of Pathology Imagebase for standardisation of prostate cancer gradingEgevad, Lars, Delahunt, Brett, Berney, Daniel M., Bostwick, David G., Cheville, John, Comperat, Eva, Evans, Andrew J., Fine, Samson W., Grignon, David J., Humphrey, Peter A., Hörnblad, Jonas, Iczkowski, Kenneth A., Kench, James G., Kristiansen, Glen, Leite, Katia R.M., Magi-Galluzzi, Cristina, Mckenney, Jesse K., Oxley, Jon, Pan, Chin-Chen, Samaratunga, Hemamali, Srigley, John R., Takahashi, Hiroyuki, True, Lawrence D., Tsuzuki, Toyonori, van der Kwast, Theo, Varma, Murali, Zhou, Ming and Clements, Mark (2018). Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 73 (1), 8-18. doi: 10.1111/his.13471 |
|
2018 Conference Publication Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniquesYaxely, J. W., Dagher, J., Delahuni, B., Egevad, L., Srigley, J. and Samaratunga, H. (2018). Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. 71st Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Melbourne Australia, Feb 24-27, 2018. HOBOKEN: WILEY. |
|
2018 Journal Article A novel technique for biobanking of large sections of radical prostatectomy specimensLindh, Claes, Delahunt, Brett, Samaratunga, Hemamali, Yaxley, John, Gudjónsdóttir, Jóna, Clements, Mark, Lindberg, Johan and Egevad, Lars (2018). A novel technique for biobanking of large sections of radical prostatectomy specimens. Histopathology, 72 (3), 481-489. doi: 10.1111/his.13386 |
|
2018 Journal Article Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniquesYaxley, J. W., Dagher, J., Delahunt, B., Egevad, L., Srigley, J. and Samaratunga, H. (2018). Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World Journal of Urology, 36 (1), 15-20. doi: 10.1007/s00345-017-2119-0 |
|
2017 Journal Article Fuhrman grading is inappropriate for papillary renal cell carcinomaDelahunt, Brett, Egevad, Lars, Srigley, John R. and Samaratunga, Hemamali (2017). Fuhrman grading is inappropriate for papillary renal cell carcinoma. World Journal of Urology, 36 (8), 1335-1336. doi: 10.1007/s00345-017-2153-y |
|
2017 Journal Article Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendationsEgevad, Lars, Delahunt, Brett, Kristiansen, Glen, Samaratunga, Hemamali and Varma, Murali (2017). Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 50 (1), 60-73. doi: 10.1016/j.pathol.2017.09.008 |
|
2017 Journal Article Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based studyKristiansen, Anna, Drevin, Linda, Delahunt, Brett, Samaratunga, Hemamali, Robinson, David, Franck Lissbrant, Ingela, Stattin, Pär and Egevad, Lars (2017). Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology, 49 (7), 715-720. doi: 10.1016/j.pathol.2017.08.008 |
|
2017 Journal Article The decline of medical publishing: the rise of the pseudo-journalDelahunt, Brett, Samaratunga, Hemamali and Egevad, Lars (2017). The decline of medical publishing: the rise of the pseudo-journal. Pathology, 49 (7), 673-674. doi: 10.1016/j.pathol.2017.08.001 |
|
2017 Journal Article Pathology Imagebase-a reference image database for standardization of pathologyEgevad, Lars, Cheville, John, Evans, Andrew J., Hornblad, Jonas, Kench, James G., Kristiansen, Glen, Leite, Katia R. M., Magi-Galluzzi, Cristina, Pan, Chin-Chen, Samaratunga, Hemamali, Srigley, John R., True, Lawrence, Zhou, Ming, Clements, Mark and Delahunt, Brett (2017). Pathology Imagebase-a reference image database for standardization of pathology. Histopathology, 71 (5), 677-685. doi: 10.1111/his.13313 |
|
2017 Journal Article Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cellsKryza, Thomas, Silva, Lakmali M., Bock, Nathalie, Fuhrman-Luck, Ruth, Stephens, Carson, Gao, Jin, Samaratunga, Hema, Lawrence, Mitchell, Hooper, John D., Dong, Ying, Risbridger, Gail and Clements, Judith A. (2017). Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Molecular Oncology, 11 (10), 1307-1329. doi: 10.1002/1878-0261.12075 |
|
2017 Journal Article Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 casesSamaratunga, Hemamali, Delahunt, Brett, Srigley, John R., Yaxley, John, Johannsen, Shulammite, Coughlin, Geoffrey, Gianduzzo, Troy, Kua, Boon, Patterson, Imogen, Nacey, John N. and Egevad, Lars (2017). Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 71 (4), 641-647. doi: 10.1111/his.13278 |
|
2017 Journal Article Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology gradingDagher, Julien, Delahunt, Brett, Rioux-Leclercq, Nathalie, Egevad, Lars, Srigley, John R, Coughlin, Geoffrey, Dunglinson, Nigel, Gianduzzo, Troy, Kua, Boon, Malone, Greg, Martin, Ben, Preston, John, Pokorny, Morgan, Wood, Simon, Yaxley, John and Samaratunga, Hemamali (2017). Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology grading. Histopathology, 71 (6), 918-925. doi: 10.1111/his.13311 |
|
2017 Journal Article Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 yearsYaxley, John W., Lah, Kevin, Yaxley, Julian P., Gardiner, Robert A., Samaratunga, Hema and MacKean, James (2017). Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. BJU International, 120 (1), 56-60. doi: 10.1111/bju.13659 |
